News
The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...
Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
InvestorsHub on MSN1d
Merck Launches Final-Stage Trial of Dengue Vaccine for ChildrenMerck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback